Moderna (MRNA) Shares Plunge Nearly 9%
Moderna (MRNA) shares tumbled by approximately 8.9%, falling below $29—marking their lowest level since April 2020, when global markets were shaken by the COVID-19 pandemic.
Since the start of 2025, MRNA’s share price has declined by around 32%.
Why Did MRNA Shares Drop?
On Monday, MRNA led the decline among US biotech stocks following the resignation of Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. Marks had held this position for over a decade.
During Trump’s first term, Marks oversaw the rollout of COVID-19 vaccines and established guidelines for emerging treatments such as cell and gene therapy.
However, in Trump’s second term, Robert F. Kennedy Jr. now serves as Health Secretary. According to The Wall Street Journal, Marks criticised Kennedy’s stance on vaccines in his resignation letter, calling it “misinformation and lies.”
The pharmaceutical industry was already under pressure amid speculation that Trump’s tariff plans could extend to prescription drugs, which are typically exempt from such measures. Marks' departure has further intensified uncertainty regarding regulatory decisions under the new administration.
Technical Analysis of MRNA Shares
The chart indicates that:
➝ The stock remains in a downtrend that began with a sharp drop in August last year (reinforced by the moving average).
➝ Over the past five months, it has been forming a descending channel (marked in red).
➝ The lower boundary of this channel acted as support yesterday.
The formation of higher lows and highs (marked in blue) had given bulls some hope in March 2025. However, yesterday’s bearish gap appears to have shattered that optimism.
It is possible that the lower blue trendline and the median of the red channel will act as resistance moving forward, further darkening the outlook for MRNA’s share price—especially given the ongoing negative news surrounding the stock.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Moderna (MRNA) shares tumbled by approximately 8.9%, falling below $29—marking their lowest level since April 2020, when global markets were shaken by the COVID-19 pandemic.
Since the start of 2025, MRNA’s share price has declined by around 32%.
Why Did MRNA Shares Drop?
On Monday, MRNA led the decline among US biotech stocks following the resignation of Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. Marks had held this position for over a decade.
During Trump’s first term, Marks oversaw the rollout of COVID-19 vaccines and established guidelines for emerging treatments such as cell and gene therapy.
However, in Trump’s second term, Robert F. Kennedy Jr. now serves as Health Secretary. According to The Wall Street Journal, Marks criticised Kennedy’s stance on vaccines in his resignation letter, calling it “misinformation and lies.”
The pharmaceutical industry was already under pressure amid speculation that Trump’s tariff plans could extend to prescription drugs, which are typically exempt from such measures. Marks' departure has further intensified uncertainty regarding regulatory decisions under the new administration.
Technical Analysis of MRNA Shares
The chart indicates that:
➝ The stock remains in a downtrend that began with a sharp drop in August last year (reinforced by the moving average).
➝ Over the past five months, it has been forming a descending channel (marked in red).
➝ The lower boundary of this channel acted as support yesterday.
The formation of higher lows and highs (marked in blue) had given bulls some hope in March 2025. However, yesterday’s bearish gap appears to have shattered that optimism.
It is possible that the lower blue trendline and the median of the red channel will act as resistance moving forward, further darkening the outlook for MRNA’s share price—especially given the ongoing negative news surrounding the stock.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Consider accessing over 700 markets with tight spreads from 0.0 pips and low commissions from $1.50 per lot.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.